Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue

References

• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–403.
   PubMed Web of Science ®Google Scholar
• Antoni S, Ferlay J, Soerjomataram I, et al. (2017). Bladder cancer incidence and mortality: a global overview and recent rrends. Eur Urol 71:96–108.
   PubMed Web of Science ®Google Scholar
• Dy GW, Gore JL, Forouzanfar MH, et al. (2017). Global burden of urologic cancers, 1990–2013. Eur Urol 71:437–46.
   PubMed Web of Science ®Google Scholar
• Cambier S, Sylvester RJ, Collette L, et al. (2016). EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta–T1 urothelial bladder cancer patients treated with 1–3 years of maintenance Bacillus Calmette–Guerin. Eur Urol 69:60–9.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Bohle A, Burger M, et al. (2017). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–61.
   PubMed Web of Science ®Google Scholar
• Chang SS, Bochner BH, Chou R, et al. (2017). Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol 198:552–9.
   PubMed Web of Science ®Google Scholar
• Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. (2016). Economic burden of bladder cancer across the European Union. Eur Urol 69:438–47.
   PubMed Web of Science ®Google Scholar
• Sievert KD, Amend B, Nagele U, et al. (2009). Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27:295–300.
   PubMed Web of Science ®Google Scholar
• Lammers RJ, Witjes JA, Inman BA, et al. (2011). The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol 60:81–93.
   PubMed Web of Science ®Google Scholar
• van Valenberg H, Colombo R, Witjes F. (2016). Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. Int J Hyperthermia 32:351–62.
   PubMed Web of Science ®Google Scholar
• Liem EI, Crezee H, de la Rosette JJ, de Reijke TM. (2016). Chemohyperthermia in non-muscle-invasive bladder cancer: an overview of the literature and recommendations. Int J Hyperthermia 32:363–73.
   PubMed Web of Science ®Google Scholar
• Arends TJ, Nativ O, Maffezzini M, et al. (2016). Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette–Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol 69:1046–52.
   PubMed Web of Science ®Google Scholar
• Wientjes MG, Badalament RA, Wang RC, et al. (1993). Penetration of mitomycin C in human bladder. Cancer Res 53:3314–20.
   PubMed Web of Science ®Google Scholar
• Williams NA, Barnard L, Allender CJ, et al. (2016). Evidence of nonuniformity in urothelium barrier function between the upper urinary tract and bladder. J Urol 195:763–70.
   PubMed Web of Science ®Google Scholar
• Colombo R, Lev A, Da Pozzo LF, et al. (1995). A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol 153:959–63.
   PubMed Web of Science ®Google Scholar
• Melicow MM. (1978). The urothelium: a battleground for oncogenesis. J Urol 120:43–7.
   PubMed Web of Science ®Google Scholar
• Lewis SA. (2000). Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol 278:F867–74.
   PubMed Web of Science ®Google Scholar
• Janssen DA, van Wijk XM, Jansen KC, et al. (2013). The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier. J Urol 189:336–42.
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Dewhirst MW. (2016). Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer. Int J Hyperthermia 32:434–45.
   PubMed Web of Science ®Google Scholar
• Arends TJ, Falke J, Lammers RJ, et al. (2015). Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. World J Urol 33:1411–7.
   PubMed Web of Science ®Google Scholar
• Curley SA, Palalon F, Lu X, Koshkina NV. (2014). Noninvasive radiofrequency treatment effect on mitochondria in pancreatic cancer cells. Cancer 120:3418–25.
   PubMed Web of Science ®Google Scholar
• Curley SA, Palalon F, Sanders KE, Koshkina NV. (2014). The effects of non-invasive radiofrequency treatment and hyperthermia on malignant and nonmalignant cells. Int J Environ Res Public Health 11:9142–53.
   PubMed Web of Science ®Google Scholar
• Ware MJ, Tinger S, Colbert KL, et al. (2015). Radiofrequency treatment alters cancer cell phenotype. Sci Rep 5:12083.
   PubMed Web of Science ®Google Scholar
• Gao X, Au JL, Badalament RA, Wientjes MG. (1998). Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin Cancer Res 4:139–43.
   PubMed Web of Science ®Google Scholar
• Wientjes MG, Dalton JT, Badalament RA, et al. (1991). Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 51:4347–54.
   PubMed Web of Science ®Google Scholar
• Paroni R, Salonia A, Lev A, et al. (2001). Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 52:273–8.
   PubMed Web of Science ®Google Scholar
• Au JL, Badalament RA, Wientjes MG, et al. (2001). Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93:597–604.
   PubMed Web of Science ®Google Scholar